Evidence map›Paper›PMID 35860221›Full record

ArticlebioRxiv : the preprint server for biology2023

Mapping SARS-CoV-2 antigenic relationships and serological responses.

Samuel H Wilks, Barbara Mühlemann, Xiaoying Shen, Sina Türeli, Eric B LeGresley, Antonia Netzl, Miguela A Caniza, Jesus N Chacaltana-Huarcaya, Victor M Corman, Xiaoju Daniell and 22 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

32 authors.

Samuel H WilksCenter for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge, CB2 3EJ, UK.
Barbara MühlemannInstitute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
Xiaoying ShenDepartment of Surgery, Duke University School of Medicine, Durham, NC, USA.
Sina TüreliCenter for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge, CB2 3EJ, UK.
Eric B LeGresleyCenter for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge, CB2 3EJ, UK.
Antonia NetzlCenter for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge, CB2 3EJ, UK.
Miguela A CanizaDepartment of Global Pediatric Medicine, Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA.
Jesus N Chacaltana-HuarcayaHospital Nacional Daniel A Carrión, Callao, Bellavista, Peru.
Victor M CormanInstitute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
Xiaoju DaniellDepartment of Surgery, Duke University School of Medicine, Durham, NC, USA.
Michael B DattoDepartment of Pathology, Duke University School of Medicine, Durham, NC, USA.
Fatimah S DawoodCenters for Disease Control and Prevention, Atlanta, GA, USA.
Thomas N DennyDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Christian DrostenInstitute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
Ron A M FouchierErasmus Medical Center, Rotterdam, Netherlands.
Patricia J GarciaSchool of Public Health, Universidad Peruana Cayetano Heredia, Lima, Peru.
Peter J HalfmannInfluenza Research Institute, Department of Pathobiological Science, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.
Agatha JassemBC Centre for Disease Control, Vancouver, British Columbia, Canada.
Lara M JeworowskiInstitute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
Terry C JonesCenter for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge, CB2 3EJ, UK.
Yoshihiro KawaokaInfluenza Research Institute, Department of Pathobiological Science, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.
Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Charlene McDanalDepartment of Surgery, Duke University School of Medicine, Durham, NC, USA.
Rolando PajonModerna, Inc., Cambridge, MA, USA.
Viviana SimonDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Melissa S StockwellDivision of Child and Adolescent Health, Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, and Department of Population and Family Health, Mailman School of Public Health, New York, NY, USA.
Haili TangDepartment of Surgery, Duke University School of Medicine, Durham, NC, USA.
Harm van BakelDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Vic VeguillaCenters for Disease Control and Prevention, Atlanta, GA, USA.
Richard WebbyDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA.
David C MontefioriDepartment of Surgery, Duke University School of Medicine, Durham, NC, USA.
Derek J SmithCenter for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge, CB2 3EJ, UK.

Funding

COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4M
Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG) - Momi-Vax DMID #21-0004 {Supplement #6}UM1AI148684 · NIAID · EMORY UNIVERSITY · PI DAVID S STEPHENS · 2020 to 2026
$77.2M
Collaborative Influenza Vaccine Innovation Centers (CIVICs): Component A: Vaccine Center75N93019C00050 · NIAID · DUKE UNIVERSITY · PI MOODY, TONY · 2019 to 2025
$69.1M
NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6M
NIAID NIH HHS 75N93019C00050NIAID NIH HHS 75N93019C00051NIAID NIH HHS 75N93021C00014NIAID NIH HHS HHSN272201400008CNIAID NIH HHS UM1 AI148684
6 · The paper itself

Abstract

During the SARS-CoV-2 pandemic, multiple variants escaping pre-existing immunity emerged, causing concerns about continued protection. Here, we use antigenic cartography to analyze patterns of cross-reactivity among a panel of 21 variants and 15 groups of human sera obtained following primary infection with 10 different variants or after mRNA-1273 or mRNA-1273.351 vaccination. We find antigenic differences among pre-Omicron variants caused by substitutions at spike protein positions 417, 452, 484, and 501. Quantifying changes in response breadth over time and with additional vaccine doses, our results show the largest increase between 4 weeks and >3 months post-2nd dose. We find changes in immunodominance of different spike regions depending on the variant an individual was first exposed to, with implications for variant risk assessment and vaccine strain selection.

Identifiers

PMID35860221
PMCPMC9298128

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.